Oral HIV-Associated Kaposi Sarcoma: A Clinical Study from the Ga-Rankuwa Area, South Africa

Table 1

Clinical and laboratory features of the patients at the time of oral HIV-KS diagnosis.

	Males	Females	Total
Number of patients (%)	17 (46%)	20 (54%)	37 (100%)
Age (years)
Mean	34	33	33.4
Range	11–55	19–46	11–55
Standard deviation	12.53	7.69	10.08
Tobacco usage (%)	7 (41%)	2 (10%)	9 (24%)
Number of patients in whom the initial presentation of HIV-KS was in the mouth	8 (47%)	13 (65%)	21 (57%)
Number of patients in whom the initial presentation of HIV-KS was concurrently in the mouth and skin	3 (18%)	3 (15%)	6 (16%)
Number of patients who developed cutaneous HIV-KS before oral HIV-KS diagnosis	6 (35%)	4 (20%)	10 (27%)
Other oral lesions present
Pseudomembranous candidiasis	7 (41%)	5 (25%)	12 (34%)
Hairy leukoplakia		1 (5%)	1 (2%)
Necrotizing gingivitis	1 (6%)		1 (2%)
Total number of patients	8 (47%)	6 (30%)	14 (38%)
Average CD4+ T-cell count at KS diagnosis (data available for 33 patients) [cells/mm^3]	141	85	107
Range	12–409	13–261	12–409
Standard deviation	117.40	77.99	106.99
Number of patients diagnosed with HIV infection and oral KS at the same time	10 (59%)	7 (35%)	17 (46%)
Number of patients who were diagnosed with HIV infection before the diagnosis of oral KS	7 (41%)	13 (65%)	20 (54%)
Number of patients with single oral HIV-KS lesions	5 (29%)	3 (15%)	8 (22%)
Number of patients with multiple oral HIV-KS lesions	12 (71%)	17 (85%)	29 (78%)
Lesion phenotype
Number of macular lesions	9 (20%)	8 (17%)	17 (18%)
Number of papular lesions	10 (22%)	11 (23%)	21 (23%)
Number of nodular lesions	16 (36%)	17 (35%)	33 (35%)
Number of exophytic lesions	10 (22%)	12 (25%)	22 (24%)
Total number of lesions	45 (100%)	48 (100%)	93 (100%)
Lesion size
Number of lesions <10 mm	15 (33%)	5 (10%)	20 (22%)
Number of lesions ≥10 mm ≤50 mm	25 (56%)	40 (83%)	65 (70%)
Number of lesions >50 mm	5 (11%)	3 (7%)	8 (8%)
Total number of lesions	45 (100%)	48 (100%)	93 (100%)